Physician profile
Scott A Coley
NPI 1184694168
$11,914.17
in general payments reported to CMS, 2019-2025
58 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $1,231 · 2021: $1,272 · 2022: $1,551 · 2023: $2,246 · 2024: $1,919 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,255.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,800.03 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $1,448.48 | 2019-2025 | |
| Novo Nordisk INC | $1,091.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,027.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $667.37 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $598.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $438.35 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $424.97 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $406.15 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.72 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $267.23 | 2019-2022 | |
| Amarin Pharma, INC. | $257.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.74 | 2019-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $202.47 | 2019-2024 | |
| Dexcom, INC. | $198.19 | 2021-2025 | Dexcom G6 Transmitter |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $182.75 | 2019-2023 | Trintellix |
| Allergan, INC. | $161.93 | 2019-2020 | |
| Exact Sciences Corporation | $156.80 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $143.59 | 2021-2025 | |
| Verona Pharma, INC. | $135.62 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $131.83 | 2023-2025 | Voquezna |
| Esperion Therapeutics, INC. | $131.44 | 2020-2025 | Nexletol |
| Neurocrine Biosciences, INC. | $122.04 | 2022-2025 | Ingrezza, Ongentys |
| Dynavax Technologies Corporation | $118.17 | 2023-2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $114.85 | 2019-2024 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $104.72 | 2022-2025 | |
| Daiichi Sankyo INC. | $97.63 | 2019-2025 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $70.35 | 2020-2021 | |
| Medtronic, INC. | $55.49 | 2024-2025 | Corevalve Evolut R, Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.62 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $48.34 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.33 | 2022 | |
| Antares Pharma, INC. | $39.77 | 2022-2025 | Xyosted |
| Inspire Medical Systems, INC. | $36.79 | 2025 | Inspire |
| Inari Medical, INC. | $36.56 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Axsome Therapeutics, INC. | $35.97 | 2025 | Symbravo, Auvelity |
| E.R. Squibb & Sons, L.L.C. | $35.76 | 2022-2023 | Eliquis |
| Edwards Lifesciences Corporation | $35.09 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lundbeck LLC | $34.68 | 2023-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $32.05 | 2019 | |
| Zimmer Biomet Holdings, INC. | $32.00 | 2025 | Persona |
| Bausch Health US, LLC | $31.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.59 | 2022 | |
| Hikma Pharmaceuticals USA | $30.38 | 2024 | Ryaltris |
| Actelion Pharmaceuticals US, INC. | $23.38 | 2025 | Opsumit, Uptravi |
| Sanofi Pasteur INC. | $22.64 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $21.87 | 2025 | Fanapt, Hetlioz |
| Mayne Pharma Commercial LLC | $19.56 | 2025 | |
| Zyla Life Sciences, INC. | $16.24 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.23 | 2023 | Onpattro |
| Tolmar, INC. | $15.61 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $15.18 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $14.28 | 2022 | |
| Intuity Medical INC | $13.20 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Currax Pharmaceuticals LLC | $13.17 | 2023 | Nexlizet, Contrave, Onzetra Xsail |
| Ironshore Pharmaceuticals INC. | $12.49 | 2019 | |
| Almatica Pharma LLC | $12.29 | 2021 | |
| Shire North American Group INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Coley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.